Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
Level 5 - mechanism / opinion, no new human data
Preclinical laboratory, cell culture, and animal models with correlative patient imaging.
PubMed 32795401 · doi:10.1016/j.ccell.2020.07.008
What was done
Integrated metabolic and epigenomic analyses were performed in H3.3K27M diffuse intrinsic pontine glioma (DIPG) cell cultures, tumor models, and via in vivo patient imaging. The authors evaluated the dependency of H3K27me3 reduction on glucose- and glutamine-derived alpha-ketoglutarate (alpha-KG), tested the therapeutic effect of inhibiting glycolysis and glutaminolysis enzymes in animal models, and examined the interaction between H3K27M and IDH1 mutations.
What was found
The abstract reports no exact quantitative values or effect sizes. H3.3K27M tumors showed increased glycolysis, glutaminolysis, and tricarboxylic acid cycle activity yielding high alpha-KG production, which maintained low H3K27me3. Pharmacologic or genetic inhibition of key glycolytic or glutaminolytic enzymes increased H3K27me3, modified chromatin accessibility, and prolonged survival in animal models. Additionally, H3K27M and IDH1 mutations were mutually exclusive and exhibited synthetic lethality.
Why it matters
This work links metabolic flux directly to epigenetic maintenance in pediatric DIPG, pointing to glycolysis and glutaminolysis pathways as potential therapeutic targets for an otherwise treatment-resistant brain cancer.
Limits
The findings derive largely from cell lines and preclinical animal models, and clinical utility in humans remains unproven. Sample sizes, specific patient imaging cohort details, and exact numerical survival gains are not reported in the abstract.
Cited by
- supports Pediatric brain tumors are metabolically dependent on both glucose and glutamine for growth.